

AMENDMENTS

IN THE CLAIMS:

Please cancel claim 9 without prejudice or disclaimer.

Please amend claims 1, 4-6 and 10-11 as follows:

B+Subt C1
~~1. (Amended) An adenosine-5'-diphosphate (ADP)-ribosylation inhibitor comprising proanthocyanidin which has been purified to a tetramer or higher fraction as an effective ingredient.~~

Subt C1
~~4. (Twice Amended) An ADP-ribosylation inhibitor according to claim 1, wherein proanthocyanidin is the one extracted with at least one solvent selected from the group consisting of water, an alcohol, and ester and a ketone.~~

B²
~~5. (Twice Amended) An ADP-ribosylation inhibitor according to claim 1, wherein proanthocyanidin is the one purified using a substance selected from the group consisting of a styrene adsorption resin, an anionic exchange resin, an octadecyl-chemically binding silica gel, an octyl-chemically binding silica gel, a phenyl-chemically binding silica gel and a silica gel.~~

Subt C1
~~6. (Twice Amended) A composition for the treatment and/or prevention of diphtheria, pertussis, tetanus and opportunistic infection, comprising as an effective ingredient an ADP-ribosylation inhibitor comprising proanthocyanidin which has been purified to a tetramer or higher fraction as an effective ingredient.~~

10. (Twice Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 7, wherein proanthocyanidin is the one extracted with at least one solvent selected from the group consisting of water, an alcohol, an ester and a ketone.

B3
11. (Twice Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 7, wherein proanthocyanidin is the one purified using a substance selected from the group consisting of a styrene adsorption resin, an anionic exchange resin, an octadecyl-chemically binding silica gel, an octyl-chemically binding silica gel, a phenyl-chemically binding silica gel and a silica gel.

✓
Please add new claims 12-21 as follows:

12. A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 2, wherein proanthocyanidin is obtained from an edible plant or an edible plant-derived material.

B4
13. A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 12, wherein said edible plant or edible plant-derived material is an extract from an apple or a grape.

14. A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 6, wherein the proanthocyanidin has been purified to a pentamer or higher fraction as an effective ingredient.

15. A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 6, wherein the proanthocyanidin has been purified to hexamer and higher fractions as an effective ingredient.

16. An adenosine-5'-diphosphate (ADP)-ribosylation inhibitor according to claim 1 comprising proanthocyanidin which has been purified to a pentamer or higher fraction as an effective ingredient.

17. An adenosine-5'-diphosphate (ADP)-ribosylation inhibitor according to claim 1 comprising proanthocyanidin which has been purified to hexamer and higher fractions as an effective ingredient.

18. A method for the treatment and/or prevention of enterotoxin type bacterial infectious disease comprising proanthocyanidin as an effective ingredient, comprising administering to a patient in need of such treatment a composition comprising proanthocyanidin.

19. A method according to claim 18, wherein the bacterial infectious disease is cholera, botulinus or traveler's diarrhea.

20. A method according to claim 18, wherein proanthocyanidin has been purified to a pentamer or higher fraction.

21. A method according to claim 18, wherein proanthocyanidin has been purified to hexamer and higher fractions.